BioSpace News Archive

Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of two posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 Digestive Disease Week® taking place in Washington, DC from May 18-21, 2024.

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months - - Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms - - Positive Interim Results are Highly Consistent with Results from the Phase 3 RESPONSE Study of Seladelpar - FOSTER CITY, Calif.--( BUSINESS WIRE )-- Gilead Sciences, Inc. (Nasdaq: GILD), following

Mirum Pharmaceuticals, Inc. announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition Annual Meeting which took place this week in Milan, Italy.

Intercept Pharmaceuticals, Inc. is presenting new data from a planned six-month analysis of its ongoing Phase 2 study 747-213 evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with primary biliary cholangitis at Digestive Disease Week® 2024 in Washington, D.C.

Boston Scientific Corporation announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator System and the EMPOWER™ Leadless Pacemaker.